Armistice Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Armistice Capital’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,629,600	Closed	-$13.8M	–	336
2025 Q2	$13.8M	Sell	1,629,600 -3,370,400	-67%	-$27M	0.24%	55
2025 Q1	$40.2M	Sell	5,000,000 -1,400,000	-22%	-$11.3M	0.6%	38
2024 Q4	$57.5M	Sell	6,400,000 -1,800,000	-22%	-$14.7M	0.78%	27
2024 Q3	$60.1M	Sell	8,200,000 -2,936,000	-26%	-$18.2M	0.96%	17
2024 Q2	$63.6M	Sell	11,136,000 -1,124,000	-9%	-$5.92M	0.8%	15
2024 Q1	$61.4M	Buy	12,260,000 +2,724,000	+29%	+$18.5M	0.81%	13
2023 Q4	$85.7M	Buy	9,536,000 +3,488,000	+58%	+$28.7M	1.17%	7
2023 Q3	$47M	Buy	6,048,000 +1,356,000	+29%	+$13.3M	0.72%	26
2023 Q2	$45.4M	Buy	4,692,000 +520,000	+12%	+$5.4M	0.66%	28
2023 Q1	$45.7M	Sell	4,172,000 -828,000	-17%	-$7.29M	0.66%	34
2022 Q4	$21.6M	Buy	5,000,000 +4,276,000	+591%	+$24.8M	0.38%	49
2022 Q3	$5.44M	Buy	+724,000	New	+$6.27M	0.09%	92
2020 Q4	–	Sell	-500,000	Closed	-$7.37M	–	108
2020 Q3	$7.37M	Buy	+500,000	New	+$7.24M	0.27%	66

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital's AUPH Position: Q3 2025 in Review

Armistice Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2025, closing a stake of 1,629,600 shares — an estimated $13.8M sold.

Armistice Capital first reported a position in AUPH in Q3 2020 and held it in 13 quarters. The position peaked at $85.7M in Q4 2023. 242 funds tracked by Wall St. Rank hold AUPH as of Q3 2025.

Armistice Capital reported no remaining Aurinia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Armistice Capital sold 1,629,600 Aurinia Pharmaceuticals shares in Q3 2025, an estimated $13.8M.
Armistice Capital first reported a position in Aurinia Pharmaceuticals in Q3 2020 and held it in 13 quarters.
Armistice Capital's Aurinia Pharmaceuticals position peaked at $85.7M in Q4 2023.
242 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.